• Member of the Executive Committee and R&D Leadership Team; Head of Program Management (Program Team Leaders and Project Managers)• Portfolio strategy and implementation including resource and budget allocation in alignment with the business growth and mission of Exo Therapeutics. • Established discovery and development program teams, R&D governance, and supported business development to pursue external opportunities.

• Head of Program Management (Program Team Leaders and Project Managers); Member of the Clinical Development Leadership Team• Led development organization build through establishment of the program management function (Program Team Leaders and Project Managers), development governance and portfolio review aligned with leading industry standards. Championed high performance teaming principles, defined the charter, roles and responsibilities of program teams with successful roll out across all development programs at H3 Biomedicine. • International Project Team Leader (IPTL) of global, matrixed development teams with overall accountability for asset strategy and execution within the Oncology Development portfolio for H3 Biomedicine and Eisai

• Development Team Leader for tipifarnib (farnesyltransferase inhibitor) with overall accountability for asset strategy and execution• Clinical pharmacologist for development portfolio

• Global Program Leader of cross-functional program teams with overall accountability for strategy and execution of assets within the R&D Immunology Portfolio• Immunology asset strategy prioritization, defining the core therapeutic indications for Translational Innovation Platform• 2013 EMD Serono Value Award (1 of 7 company-wide)

• Global Project Leader of global, matrixed project teams with overall accountability for strategy and execution of assets within the Oncology Development Portfolio• Led division initiative to pilot project pathway teams, aimed at maximizing synergies across teams focused on similar mechanism of action and biological pathways.

• Project Clinical Pharmacologist for Vedolizumab (ENTYVIO) and brentuximab vedotin (anti- CD30 ADC); key contributor to the global development, submission and approvals• Outstanding Individual Contributor Award – 2008

• Clinical Pharmacology lead for the CTD preparation and defense of Qlaira® (estradiol valerate/dienogest), approved in the EU• Individual Achievement Award (CITE) – 2004, 2005 and 2006• Completed a 2-year Expatriate program at the corporate headquarters in Berlin, Germany• Selected to participate in the Corporate Leadership Program (Duke University) and BSP Assessment Center

• Characterized the pharmacokinetics and pharmacodynamics of various anticancer agents in preclinical, Phase I, and Phase II drug development• Developed and validated analytical assays utilizing HPLC, GC/MS, and LC/MS/MS instrumentation